Detalles de la búsqueda
1.
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Mult Scler
; 28(10): 1591-1605, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35380078
2.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Mult Scler
; 28(10): 1526-1540, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35261318
3.
Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.
J Headache Pain
; 23(1): 104, 2022 Aug 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35978286
4.
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Mult Scler
; 27(14): 2219-2231, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33769117
5.
Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
Cephalalgia
; 41(11-12): 1262-1267, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33939497
6.
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
Cephalalgia
; 40(1): 28-38, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31816249
7.
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
J Neurol Neurosurg Psychiatry
; 87(5): 468-75, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26111826
8.
Aphid-encoded variability in susceptibility to a parasitoid.
BMC Evol Biol
; 14: 127, 2014 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24916045
9.
Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
JAMA Neurol
; 81(5): 461-470, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526461
10.
Burden of migraine in patients attending Belgian headache specialists: real-world evidence from the BECOME study.
Acta Neurol Belg
; 123(4): 1495-1503, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37209257
11.
Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study.
Pain Ther
; 12(2): 575-591, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36842093
12.
Factors that affect migratory Western Atlantic red knots (Calidris canutus rufa) and their prey during spring staging on Virginia's barrier islands.
PLoS One
; 17(7): e0270224, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35776754
13.
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
J Neurol
; 269(9): 5093-5104, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35639197
14.
Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study.
Pain Ther
; 10(2): 1691-1708, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34643891
15.
Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.
J Neurol
; 265(2): 348-355, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29243005
16.
A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.
Mult Scler J Exp Transl Clin
; 3(3): 2055217317730096, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28989795
17.
The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.
J Neurol
; 263(2): 299-305, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26568562
18.
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
J Neurol
; 263(2): 354-360, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26645392
19.
Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Neurology
; 84(15): 1582-91, 2015 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-25795646
20.
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings.
Mult Scler Relat Disord
; 3(4): 494-504, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25877062